NTRA News and Press, Natera Inc. From 07/07/23

2023-07-07 10:45:34 ET Update 10:45 AM EST: Adds comments from Craig Hallum Diagnostics firm Castle Biosciences ( NASDAQ: CSTL ) added ~41% in the morning hours Friday in a move attributed to an unexpected policy reversal regarding Medicare coverage for the company’s ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA. A live webcast and audio ar...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Prospera test being presented at the American Transplant Congress (ATC) 2023 taking place June 3-7, 2023. The presentations include several interim analyses from ProActive, a prospective donor...

2023-06-02 01:29:17 ET Summary Duquesne Family Office's 13F portfolio value increased by 14% to $2.31B in Q1 2023, with 29 securities significantly large. Microsoft, Alphabet, Amazon, IQVIA Holdings, News Corp, and Taiwan Semi were among the new stakes established during the quart...

Highlights include oral presentations in Sarcoma and CRC; immunotherapy monitoring data from the Phase 3 EMPOWER-Lung 1 study; updates from the CIRCULATE-Japan study in CRC Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its pe...

2023-05-19 11:54:31 ET Summary Natera reported outstanding Q1 2023 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. The company's product revenues witnessed a dramatic 25.2% growth due to increased test volumes, han...

2023-05-17 12:37:04 ET Summary Today, we revisit genetic testing concern Natera, Inc., as the shares are up more than 30% so far in 2023. The company continues to deliver solid revenue growth even as its cash burn rate remains a concern. Which way do Natera, Inc. shares go fro...

2023-05-15 16:59:32 ET Invitae ( NYSE: NVTA ) said it will appeal a verdict in a patent case in a federal court in Delaware that found in favor of Natera ( NTRA ). Invitae ( NVTA ) has been ordered to pay $19.35M for infringing some Natera ( NTRA ) patents. The...

Natera has a broad, global IP portfolio of more than 360 issued or pending patents, with more than 180 in the field of oncology/MRD Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaw...

2023-05-09 23:07:08 ET Natera, Inc. (NTRA) Q1 2023 Earnings Conference Call May 09, 2023, 04:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Alexey Aleshin - Chief Medical Officer John Fesko - Ch...